Cytomed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy